JOP20210048B1 - أجسام مضادة مساعدة لـ cd200r واستخداماتها - Google Patents

أجسام مضادة مساعدة لـ cd200r واستخداماتها

Info

Publication number
JOP20210048B1
JOP20210048B1 JOJO/P/2021/0048A JOP20210048A JOP20210048B1 JO P20210048 B1 JOP20210048 B1 JO P20210048B1 JO P20210048 A JOP20210048 A JO P20210048A JO P20210048 B1 JOP20210048 B1 JO P20210048B1
Authority
JO
Jordan
Prior art keywords
antibodies
cd200r
adjuvant
gvhd
ibd
Prior art date
Application number
JOJO/P/2021/0048A
Other languages
Arabic (ar)
English (en)
Inventor
Scott Charles Potter
Stephen John Demarest
Diana Isabel Ruiz
Anja Koester
Payal Mehta
Xiufeng Wu
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20210048A1 publication Critical patent/JOP20210048A1/ar
Application granted granted Critical
Publication of JOP20210048B1 publication Critical patent/JOP20210048B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2021/0048A 2018-09-14 2021-03-11 أجسام مضادة مساعدة لـ cd200r واستخداماتها JOP20210048B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
PCT/US2019/050511 WO2020055943A1 (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JOP20210048A1 JOP20210048A1 (ar) 2021-03-11
JOP20210048B1 true JOP20210048B1 (ar) 2024-12-22

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2021/0048A JOP20210048B1 (ar) 2018-09-14 2021-03-11 أجسام مضادة مساعدة لـ cd200r واستخداماتها

Country Status (27)

Country Link
US (2) US11319370B2 (enExample)
EP (1) EP3849667A1 (enExample)
JP (3) JP7185051B2 (enExample)
KR (1) KR102705378B1 (enExample)
CN (2) CN118530360A (enExample)
AR (1) AR116668A1 (enExample)
AU (1) AU2019339334B2 (enExample)
BR (1) BR112021003254A2 (enExample)
CA (1) CA3112763C (enExample)
CL (1) CL2021000606A1 (enExample)
CO (1) CO2021003093A2 (enExample)
CR (1) CR20210134A (enExample)
DO (1) DOP2021000040A (enExample)
EA (1) EA202190530A1 (enExample)
EC (1) ECSP21017619A (enExample)
IL (1) IL281442B2 (enExample)
JO (1) JOP20210048B1 (enExample)
MA (1) MA53604A (enExample)
MX (1) MX2021003026A (enExample)
MY (1) MY196156A (enExample)
NZ (1) NZ773626A (enExample)
PE (1) PE20211742A1 (enExample)
PH (1) PH12021550530A1 (enExample)
SG (1) SG11202101697YA (enExample)
TW (1) TWI749367B (enExample)
WO (1) WO2020055943A1 (enExample)
ZA (2) ZA202101246B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021243204A1 (en) * 2020-05-29 2021-12-02 23Andme, Inc. Anti-cd200r1 antibodies and methods of use thereof
AU2023251091A1 (en) * 2022-04-06 2024-10-10 Gilead Sciences, Inc. Engineered cd200r antibodies and uses thereof
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
IL325073A (en) 2023-06-02 2026-02-01 Aimed Bio Inc Anti-CD200R1 antibody and its uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
US8075884B2 (en) * 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
KR20090094846A (ko) * 2006-12-22 2009-09-08 쉐링 코포레이션 Ｃｄ200ｒ에 대한 항체
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
BR112012020101A2 (pt) * 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
NZ773626A (en) 2024-11-29
PH12021550530A1 (en) 2022-02-14
SG11202101697YA (en) 2021-04-29
MA53604A (fr) 2021-12-22
ZA202101246B (en) 2023-04-26
US20220251198A1 (en) 2022-08-11
JOP20210048A1 (ar) 2021-03-11
JP2024105529A (ja) 2024-08-06
CR20210134A (es) 2021-03-29
CO2021003093A2 (es) 2021-03-19
CN112739422A (zh) 2021-04-30
IL281442A (en) 2021-04-29
MX2021003026A (es) 2021-05-27
KR20210044262A (ko) 2021-04-22
CA3112763A1 (en) 2020-03-19
TW202024132A (zh) 2020-07-01
IL281442B1 (en) 2023-11-01
AU2019339334B2 (en) 2023-03-09
PE20211742A1 (es) 2021-09-06
JP2022500080A (ja) 2022-01-04
JP7490025B2 (ja) 2024-05-24
EP3849667A1 (en) 2021-07-21
AU2019339334A1 (en) 2021-03-18
ECSP21017619A (es) 2021-04-29
CN112739422B (zh) 2024-05-28
IL281442B2 (en) 2024-03-01
JP2022141959A (ja) 2022-09-29
KR102705378B1 (ko) 2024-09-12
CN118530360A (zh) 2024-08-23
MY196156A (en) 2023-03-17
US11319370B2 (en) 2022-05-03
DOP2021000040A (es) 2021-03-31
US20200087395A1 (en) 2020-03-19
TWI749367B (zh) 2021-12-11
AR116668A1 (es) 2021-06-02
ZA202204978B (en) 2022-09-28
JP7185051B2 (ja) 2022-12-06
WO2020055943A1 (en) 2020-03-19
CA3112763C (en) 2024-05-14
BR112021003254A2 (pt) 2021-05-18
CL2021000606A1 (es) 2021-09-20
EA202190530A1 (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
PH12021550530A1 (en) Cd200r agonist antibodies and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12019502283A1 (en) Anti-lag3 antibodies
WO2017218707A3 (en) Bispecific checkpoint inhibitor antibodies
MX2019007121A (es) Anticuerpos anti-ox40 y sus usos.
GEAP202014668A (en) Lag-3-binding molecules and methods of use thereof
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
EA201691787A1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
MY209528A (en) Anti-il-33 antibodies and uses thereof
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MY193674A (en) Anti-transthyretin antibodies
GEAP202114983A (en) Anti-coagulation factor xi antibodies
TN2018000289A1 (en) Antibodies for il-17c
PH12020550023A1 (en) Compositions for treating stress-related disorders
ZA201807816B (en) Anti-il-22r antibodies
PH12017501872A1 (en) Methods of treating diseases
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии
EA202090330A1 (ru) Композиции и способы лечения расстройств, связанных со стрессом
EA202090128A2 (ru) Антитела против антигена 2 дендритных клеток крови и их применение